Optimal management of peptic ulcer disease in the elderly

Drugs and Aging

Volumn 27, Issue 7, 2010, Pages 545-558

  Pilotto, Alberto ^a   Franceschi, Marilisa ^b   Maggi, Stefania ^c   Addante, Filomena ^a   Sancarlo, Daniele ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b Endoscopy Unit   (Italy)

^c CNR   (Italy)

Author keywords

Elderly; Peptic ulcer, treatment; Proton pump inhibitors, therapeutic use.

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMOXICILLIN; ANTITHROMBOCYTIC AGENT; BISMUTH; CELECOXIB; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 2C19; GATIFLOXACIN; HEMOGLOBIN; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; TINIDAZOLE; UREA; WARFARIN; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

ABDOMINAL PAIN; AGED; ANEMIA; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BLOOD PRESSURE; CAMPYLOBACTER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COGNITIVE DEFECT; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPIC THERAPY; EUROPE; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; HEART FAILURE; HEART RATE; HELICOBACTER INFECTION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER FAILURE; MALNUTRITION; MELENA; MORTALITY; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SALMONELLA; SEX DIFFERENCE; STOMACH ACID; STOMACH ULCER; SYNCOPE; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; PEPTIC ULCER BLEEDING;

AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PROTON PUMP INHIBITORS;

EID: 77954155802     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11537380-000000000-00000     Document Type: Review

References (98)

1. Guralnik JM, Ferrucci L. Demography and epidemiology. In: Halter JB, Ouslander JG, Tinetti ME, et al., editors. Hazzard's geriatric medicine and gerontology. 6th ed. New York: McGraw Hill, 2009: 45-67
2. Pilotto A, Malfertheiner P. Review article: an approach to Helicobacter pylori infection in the elderly. Aliment Pharmacol Ther 2002; 16: 683-691
3. Pilotto A, Franceschi M, Di Mario F. Helicobacter pyloriassociated peptic ulcer disease in elderly patients. Clin Geriatr 2000; 8: 49-58
4. Hilton D, Iman N, Burke GJ, et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001; 96: 380-384
5. Pilotto A, Maggi S, Noale M, et al., on behalf of the IPOD Investigators. Development and validation of a new questionnaire for the evaluation of upper gastrointestinal symptoms in the elderly population: a multicenter study. J Gerontol A Biol Sci Med Sci 2010; 65: 174-178
6. Pilotto A, Franceschi M, Leandro G, et al. Clinical features of reflux esophagitis in the elderly: a study of 840 consecutive patients. J Am Geriatr Soc 2006; 54: 1537-1542
7. Malfertheiner P, Chan FKL, McColl EL. Peptic ulcer disease. Lancet 2009; 374: 1449-1461
8. Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nature Clin Pract Gastroenterol Hepatol 2006; 3: 80-89
9. Pilotto A. Helicobacter pylori-associated peptic ulcer disease in older patients: current management strategies. Drugs Aging 2001; 18: 487-494
10. Ford A, Delaney B, Forman D, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2004; (4): CD003840
11. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in themanagement ofHelicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 (Pubitemid 46854190)
12. Pilotto A, Franceschi M, Perri F, et al. Treatment options for Helicobacter pylori in the elderly. AgingHealth 2006; 2: 661-668
13. Tong JL, Ran ZH, Shen J, et al. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009; 34: 41-53
14. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005; 21: 1419-1424
15. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-325
16. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44
17. Sharara AI, Chaar HF, Racoubian E, et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 2004; 9: 255-261
18. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2004; 20: 1181-1188
19. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825
20. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562
21. Pilotto A, Franceschi M, Leandro G, et al. Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Aliment Pharmacol Ther 2001; 15: 1031-1036
22. Moshkowitz M, Brill S, Konikoff FM, et al. The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive patients with dyspepsia. J Am Geriatr Soc 1999; 47: 720-722
23. Pilotto A, FranceschiM, Leandro G, et al. Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. J Gastroenterol Hepatol 1999; 14: 464-471
24. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 13-24
25. Pilotto A, Rassu M, Leandro G, et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000; 32: 763-768
26. Parsons HK, Carter MJ, Sanders DS, et al. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. Aliment Pharmacol Ther 2001; 15: 1473-1478
27. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088-1094
28. Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch Intern Med 1999; 159: 2312-2319
29. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-1031
30. Padol S, Yuan YH, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-1475
31. Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is amajor predictor of treatment failure in White patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004; 76: 201-232
32. Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001; 15: 1479-1484
33. Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-573
34. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomicsbased tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81: 521-528
35. Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008; 47: 1-6
36. Pilotto A, Addante F, D'Onofrio G, et al. The comprehensive geriatric assessment and the multidimensional approach: a new look at the older patient with gastroenterological disorders. Best Pract Clin Res Gastroenterol 2009; 23: 829-837
37. Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007; 132: 498-506
38. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-828
39. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional nonaspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738
40. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-1626
41. Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on non-steroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Non-Steroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103: 2908-2918
42. Leandro G, Pilotto A, Franceschi M, et al. Prevention of acute NSAID-related gastroduodenal damage: a metaanalysis of controlled clinical trials. Dig Dis Sci 2001; 46: 1924-1936
43. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 1091-1097
44. Pilotto A, FranceschiM, Leandro G, et al. The risk of upper gastrointestinal bleeding in elderly users of aspirin and other nonsteroidal antiinflammatory drugs: the role of gastroprotective drugs. Aging Clin Exp Res 2003; 15: 494-499
45. Pilotto A, Franceschi M, Longo MG, et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis 2004; 36: 666-670
46. Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007; 26: 265-275
47. Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007; 24: 121-131
48. Pilotto A, Di Mario F, Franceschi M, et al. Pantoprazole versus one-week H. pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000; 14: 1077-1082
49. Chan FKL, Chung SCS, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973
50. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
51. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996; 348: 1329-1339
52. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl JMed 2001; 345: 494-502
53. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95: 2218-2224
54. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-830
55. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis. BMJ 2000; 321: 1183-1187
56. McQuaid KR, Laine L. Systematic review andmeta-analysis of adverse events of low-dose aspirin and clopidogrel randomized controlled trials. Am J Med 2006; 199: 624-638
57. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirinassociated major upper-gastrointestinal bleeding with enteric- coated or buffered product. Lancet 1996; 348: 1413-1416
58. Pilotto A, Franceschi M, Leandro G, et al. Helicobacter pylori infection and the risk of gastroduodenal damage in symptomatic elderly chronic low-dose aspirin users: effect of antisecretory drugs. Age Ageing 2004; 33: 402-404
59. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038
60. Taha AS,McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 119-125
61. Chan FK, Chinh JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-244
62. Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 860-865
63. Ho PM, Maddox T, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944
64. Lanas A, García-Rodríguez LA, Arroyo MT, et al., Investigators of the Asociació n Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal antiinflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507-515
65. Lanza F, Rack MF, Simon TJ, et al. Effects of alendronate on gastric and duodenal mucosa. AmJGastroenterol 1998; 93: 753-757
66. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-638
67. Graham DY, Malaty HM, Goodgame R. Primary aminobisphosphonates: a new class of gastrotoxic drugs: comparison of alendronate and aspirin. Am J Gastroenterol 1997; 92: 1322-1325
68. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002; 77: 1031-1043
69. Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal anti-inflammatory drug therapy. J Gastroenterol 2009; 44: 113-120
70. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006; 119: 719-727
71. Vidal X, Ibáñez L, Vendrell L, et al., Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31: 159-168
72. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475-1482
73. Pilotto A, Franceschi M. Upper gastrointestinal disorders. In: Halter JB, Ouslander JG, Tinetti ME, et al., editors. Hazzard's geriatric medicine and gerontology. 6th ed. New York: McGraw Hill, 2009: 1075-1090
74. Hung C, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology 2005; 128: 1845-1850
75. Andriulli A, Annese V, Caruso N, et al. Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses.Am JGastroenterol 2005; 100: 207-219
76. Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316-321
77. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318-1321
78. Masaoka T, Suzuki H, Hori S, et al. Blatchford scoring system is a useful scoring system for detecting patients with upper gastrointestinal bleeding who do not need endoscopic intervention. J Gastroenterol Hepatol 2007; 22: 1404-1408
79. Romagnuolo J, Barkun AN, Enns R, et al. Simple clinical predictors may obviate urgent endoscopy in selected patients with nonvariceal upper gastrointestinal tract bleeding. Arch Intern Med 2007; 167: 265-270
80. StanleyAJ,AshleyD,MowatC, et al.Outpatientmanagement of patients with low-risk upper gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet 2009; 373: 42-47
81. Cooper GS, Kou TD, Wong RCK. Outpatient management of nonvariceal upper gastrointestinal hemorrhage: unexpected mortality in Medicare beneficiaries. Gastroenterology 2009; 136: 108-114
82. Pilotto A, Ferrucci L, Scarcelli C, et al. Usefulness of the comprehensive geriatric assessment in older patients with upper gastrointestinal bleeding: a two-year follow-up study. Dig Dis 2007; 25: 124-128
83. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acidsuppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418-1423
84. Dial S, Delaney C, Schneider V, et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficileassociated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175: 745-748
85. Pilotto A, Franceschi M, Vitale D, et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 2008; 103: 2816-2823
86. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infections in patients taking acid suppression therapy. Am J Gastroenterol 2007; 102: 2047-2056
87. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-778
88. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-790
89. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004; 292: 1955-1960
90. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-955
91. Sarkar M, Hennessy S, Yang YX. Proton pump inhibitor use and the risk of community-acquired pneumonia. Ann Intern Med 2008; 149: 391-398
92. Schenk BE, Festen HP, Kuipers EJ, et al. Effect of shortand long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996; 10: 541-545
93. den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27: 491-497
94. Yang Y, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953
95. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 12: 319-326
96. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 2009; 169: 1952-1960
97. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the women's health initiative. Arch Intern Med 2010; 170: 765-771.
98. Correspondence: Dr Alberto Pilotto, Geriatric Unit and Gerontology-Geriatrics Research Laboratory, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, San Giovanni Rotondo (FG), I-71013, Italy.